References
- To T, Viegi G, Cruz A, et al. A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals. Eur Respir J. 2020;23, 56(1):2001704.
- Jindal SK, Jindal A, Moitra S. Problems of management of non‑corona respiratory diseases in the era of COVID‑19. Int J Non Commun Dis. 2020;5:63–69.
- Chatterjee P, Anand T, Singh KJ, et al. Healthcare workers & SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19. Indian J Med Res. 2020;151(5):459–467.
- Tuberculosis BD. COVID-19, and the end tuberculosis strategy in India. Lung India. 2020;37:467–472.
- National strategic plan 2017-2025 for TB elimination in India. [cited 2021 Jan 7]. Available from: www.https://tbcindia.gov.in/.
- Sachdeva KS. Accelerating progress towards ending tuberculosis in India. Ind J Med Res. 2020;151:266–268.
- Golandaj JA. Insight into the COVID-19 led slow-down in TB notifications in India. Ind J Tuberculosis. 2021;68:142–145.
- Datta B, Jaiswal A, Goyal P, et al. The untimely demise of the TB Free block model in the wake of coronavirus disease 2019 in India. Trans R Soc Trop Med Hyg. 2020;114(11):789–791.
- McQuaid CF, McCreesh N, Read JM, et al. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J. 2020;56:2001718.
- Covid pushes TB patients to brink. [cited 2021 Apr 24]. Available from: https://www.tribuneindia.com/news/punjab/covid-pushes-tb-patients-to-brink-195307.
- Salvi SS, Dhar R, Mahesh PA, et al. COPD management during the COVID-19 pandemic. Lung India. 2021;38:80–85.
- Rai DK, Karmaker S. Has respiratory emergencies changed during lockdown implemented for COVID-19 pandemic? J Family Med Primary Care. 2020;9(10):5384.
- Kumar R, Behera D, Jindal SK, et al. Post-COVID-19 respiratory management: expert panel report. Indian J Chest Dis Allied Sci. 2020;62:179–191.
- Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: the tsunami that will follow the earthquake. Lung India. 2021;38:41–47.
- George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Resp Med. 2020;8(8):807–815.